Seminars in Hematology
Volume 46, Issue 3 , Pages 230-247 , July 2009

Antiviral Therapy in Patients With Hematologic Malignancies, Transplantation, and Aplastic Anemia

  • Timothy Jancel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Timothy Jancel, PharmD, National Institutes of Health, Building 10, Room 1N257, 10 Center Dr, Bethesda, MD 20892-1196
    • ,
  • Scott R. Penzak

References 

  1. Meyers JD. Chemoprophylaxis of viral infection in immunocompromised patients. Eur J Cancer Clin Oncol. 1989;25:1369–1374
  2. Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes. 2006;13:60–65
  3. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis. 2007;196:266–270
  4. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH. Herpes simplex virus resistant to acyclovir (A study in a tertiary care center). Ann Intern Med. 1990;112:416–422
  5. McLaren C, Chen MS, Ghazzouli I, Saral R, Burns WH. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agents Chemother. 1985;28:740–744
  6. van Burik JA, Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematol Oncol Clin North Am. 1999;13:1065–1089
  7. Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999;94:4029–4035
  8. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978–1985
  9. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  10. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–178
  11. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179–184
  12. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–1164
  13. Zaia JA. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin Infect Dis. 1993;17(Suppl 2):S392–S399
  14. Englund JA. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol Blood Marrow Transplant. 2001;7(Suppl):2S–4S
  15. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–874
  16. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110:1681–1688
  17. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143:455–467
  18. Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood. 2004;103:1611–1617
  19. Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–2119
  20. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J. 2007;26:1089–1093
  21. Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis. 2003;3:79–86
  22. Echavarría M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21:704–715
  23. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169:775–781
  24. Robin M, Marque-Juillet S, Scieux C, Peffault de Latour R, Ferry C, Rocha V, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica. 2007;92:1254–1257
  25. van Tol MJ, Kroes AC, Schinkel J, Dinkelaar W, Claas EC, Jol-van der Zijde CM, et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36:39–50
  26. Arav-Boger R, Echavarria M, Forman M, Charache P, Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J. 2000;19:1097–1100
  27. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:1290–1297
  28. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:388–394
  29. Emovon OE, Lin A, Howell DN, Afzal F, Baillie M, Rogers J, et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant. 2003;18:2436–2438
  30. Leruez-Ville M, Minard V, Lacaille F, Buzyn A, Abachin E, Blanche S, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis. 2004;38:45–52
  31. Muller WJ, Levin MJ, Shin YK, Robinson C, Quinones R, Malcolm J, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005;41:1812–1816
  32. Hatakeyama N, Suzuki N, Kudoh T, Hori T, Mizue N, Tsutsumi H. Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J. 2003;22:928–929
  33. Wagstaff AJ, Faulds D, Goa KL. Aciclovir (A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy). Drugs. 1994;47:153–205
  34. Balfour H. Prevention of cytomegalovirus disease. Int J Antimicrob Agents. 1996;7:283–285
  35. Meyers JD. Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant. 1988;3:95–104
  36. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977;74:5716–5720
  37. Elion GB. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother. 1983;12(Suppl B):9–17
  38. Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978;253:8721–8727
  39. Beutner K. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. 1995;28:281–290
  40. O'Brien JJ, Campoli-Richards DM. Acyclovir (An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy). Drugs. 1989;37:233–309
  41. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect. 1996;33:235–248
  42. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat. 2002;5:88–114
  43. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA. 1990;263:1662–1664
  44. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1991;35:2322–2328
  45. Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990;112:187–191
  46. Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994;170:68–75
  47. Larder BA, Cheng YC, Darby G. Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. J Gen Virol. 1983;64:523–532
  48. Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982;73:186–192
  49. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29–37
  50. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39:2759–2764
  51. Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet. 1983;8:187–201
  52. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595–605
  53. Feinberg JE, Hurwitz S, Cooper D, Sattler FR, MacGregor RR, Powderly W, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1998;177:48–56
  54. Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J. 1994;87:1227–1231
  55. Schreiber R, Wolpin J, Koren G. Determinants of aciclovir-induced nephrotoxicity in children. Paediatr Drugs. 2008;10:135–139
  56. Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS. 2005;19:455–462
  57. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant. 2003;31:51–55
  58. Biron KK, Elion GB. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980;18:443–447
  59. Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother. 1996;37:303–313
  60. Perry CM, Wagstaff AJ. Famciclovir (A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections). Drugs. 1995;50:396–415
  61. Weinberg A, Bate BJ, Masters HB, Schneider SA, Clark JC, Wren CG, et al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1992;36:2037–2038
  62. Standring-Cox R, Bacon TH, Howard BA. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir. J Virol Methods. 1996;56:3–11
  63. Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother. 1987;31:1238–1242
  64. Vere Hodge RA, Darlison SJ, Earnshaw DL, Readshaw SA. Use of isotopically chiral [4′-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase. Chirality. 1993;5:583–588
  65. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother. 1989;33:1765–1773
  66. Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol. 2003;148:1757–1769
  67. Boyd MR, Bacon TH, Sutton D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother. 1988;32:358–363
  68. Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol. 1996;15(Suppl 1):14–26
  69. Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther. 1994;55:418–426
  70. Pue MA, Bent LZ. Pharmacokinetics of famciclovir in man. Antiv Chem Chemother. 1993;4:47–55
  71. Pue MA, Pratt SK, Fairless AJ, Fowles S, Laroche J, Georgiou P, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother. 1994;33:119–127
  72. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994;38:2454–2457
  73. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001;19:13–22
  74. Schacker T, Hu HL, Koelle DM, Zeh J, Saltzman R, Boon R, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons (A double-blind, placebo-controlled trial). Ann Intern Med. 1998;128:21–28
  75. Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS. 2000;14:1211–1217
  76. Curran M, Noble S. Valganciclovir. Drugs. 2001;61:1145–1150
  77. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature. 1992;358:162–164
  78. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis. 1999;1:105–114
  79. Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol. 2005;77:425–429
  80. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71:154–163
  81. Avery RK. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis. 2008;21:433–437
  82. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167–176
  83. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002;72:142–150
  84. Noble S, Faulds D. Ganciclovir (An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients). Drugs. 1998;56:115–146
  85. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, et al. Valganciclovir Study Group A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119–1126
  86. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611–620
  87. Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65:859–878
  88. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation. 2005;79:85–90
  89. Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant. 2005;5:1462–1468
  90. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant. 2008;8:158–161
  91. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182–1186
  92. Valcyte. [package insert] Nutley, NJ: Roche Laboratories; 2006;
  93. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1997;126:257–263
  94. De Clercq E, Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov. 2005;4:928–940
  95. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol. 1998;72:5927–5936
  96. Safrin S. Treatment of acyclovir resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr. 1992;5(Suppl):S29–S32
  97. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995;39:1247–1252
  98. Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A, et al. Pharmacokinetics, safety and bioavailability of cidofovir in HIV-infected subjects. Antiviral Res. 1996;29:153–161
  99. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36:127–143
  100. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000;11:383–393
  101. Vistide. [package insert] Foster City, CA: Gilead Sciences Inc; 2000;
  102. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981;6:135–151
  103. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood. 2001;97:388–392
  104. Cesaro S, Zhou X, Manzardo C, Buonfrate D, Cusinato R, Tridello G, et al. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. J Clin Virol. 2005;34:129–132
  105. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006;43:331–339
  106. La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;32:871–876
  107. Brody SR, Humphreys M, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther. 1999;65:21–28
  108. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992;92:3S–7S
  109. Chrisp P, Clissold SP. Foscarnet (A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis). Drugs. 1991;41:104–129
  110. Weinberg A, Jabs DA, Chou S, Martin BK, Lurain NS, Forman MS, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187:777–784
  111. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant. 2007;26:1286–1292
  112. Oshima K, Kanda Y, Kako S, Asano-Mori Y, Watanabe T, Motokura T, et al. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol. 2008;80:1769–1775
  113. Sjövall J, Karlsson A, Ogenstad S, Sandström E, Saarimäki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther. 1988;44:65–73
  114. Sjövall J, Bergdahl S, Movin G, Ogenstad S, Saarimäki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1989;33:1023–1031
  115. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989;33:742–745
  116. Klintmalm G, Lönnqvist B, Oberg B, Gahrton G, Lernestedt JO, Lundgren G, et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis. 1985;17:157–163
  117. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes. 2004;11:77–86
  118. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis. 2001;3(Suppl 2):20–24
  119. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37:471–484
  120. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363–1373
  121. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998;42:640–646
  122. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264–2272
  123. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001;49:147–156
  124. Centers for Disease Control and Prevention. CDC issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza a (H1N1) viruses, 2008-09 influenza season. http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279Accessed February 5, 2009
  125. Tamiflu. [package insert] Nutley, NJ: Roche Laboratories; 2008;
  126. Mayersohn M. Special pharmacokinetic considerations in the elderly. In:  Evans WE,  Schentag JJ,  Jusko WJ editor. Applied pharmacokinetics: principles of therapeutic drug monitoring. Vancouver, WA: Applied Therapeutics Inc; 1992;p. 9.1–9.43
  127. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009;37:315–321
  128. Morimoto K, Nakakariya M, Shirasaka Y, Kakinuma C, Fujita T, Tamai I, et al. Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos. 2008;36:6–9
  129. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002;30:13–19
  130. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother. 2008;52:3013–3021
  131. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol. 2008;48:935–947
  132. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Safety. 2003;26:787–801
  133. McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother. 2001;35:57–70
  134. Woods JM, Bethell RC, Coates JA, Healy N, Hiscox SA, Pearson BA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 1993;37:1473–1479
  135. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363:418–423
  136. Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. 1994;25:123–131
  137. Cheer SM, Wagstaff AJ. Zanamivir: An update of its use in influenza. Drugs. 2002;62:71–106
  138. Relenza. [package insert] Research Triangle Park, NC: GlaxoSmithKline; 2008;
  139. Dunn CJ, Goa KL. Zanamivir: A review of its use in influenza. Drugs. 1999;58:761–784
  140. Cass LMR, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl 1):1–11
  141. Peng AW, Hussey EK, Moore KH. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. J Clin Pharmacol. 2000;40:242–249
  142. Cass LMR, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36(Supp1 1):21–31
  143. Cass LM, Efthymiopoulos C, Marsh J, Bye A. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet. 1999;36(Suppl 1):13–19
  144. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet. 1999;36(Suppl 1):41–50
  145. Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: A review of clinical safety. Drug Saf. 1999;21:267–281
  146. Gravenstein S, Johnston SL, Loeschel E, Webster A. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug Saf. 2001;24:1113–1125
  147. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367:303–313
  148. Symmetrel. [package insert] Chadds Ford, PA: Endo Pharmaceuticals; 2007;
  149. Flumadine. [package insert] St. Louis, MO: Forest Pharmaceuticals, Inc; 2006;
  150. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet. 1987;13:141–178
  151. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14:35–51
  152. Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Morselli PL. Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol. 1976;3:883–889
  153. Postma JU, Tilburg WV. Visual hallucinations and delirium during treatment with amantadine. J Am Geriatr Soc. 1975;23:212–215
  154. Wellbutrin XL. [package insert] Research Triangle Park, NC: GlaxoSmithKline; 2008;
  155. Wilson TW, Rajput AH. Amantadine–Dyazide interaction. Can Med Assoc J. 1983;129:974–975
  156. K-Dur. [package insert] Kenilworth, NJ: Key Pharmaceuticals Inc; 2004;
  157. Klor-con. [package insert] Minneapolis, MN: Upsher-Smith Laboratories Inc; 2005;
  158. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother. 1995;29:299–310
  159. Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987;31:1140–1142
  160. Wills RJ, Belshe R, Tomlinsin D, De Grazia F, Lin A, Wells S, et al. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease. Clin Pharmacol Ther. 1987;42:449–454
  161. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668
  162. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA, Davis MG, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46:2365–2372
  163. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46:2969–2976
  164. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47:1334–1342
  165. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37:124–127
  166. National Institutes of Health. Prophylactic use of maribavir for the prevention of cytomegalovirus (CMV) disease in stem cell transplant recipients. In: ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00411645?term=maribavir&rank=3NLM Identifier: NCT00411645. Accessed February 13, 2009
  167. National Institutes of Health. Maribavir versus oral ganciclovir for the prevention of cytomegalovirus (CMV) disease in liver transplant recipients. In: ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00497796?term=maribavir&rank=23NLM Identifier: NCT00497796. Accessed February 13, 2009
  168. Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003;59:163–171
  169. Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 2005;49:656–662
  170. National Institutes of Health. CMX001 in post-transplant patients with BK virus viruria. In: ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00793598?term=cmx001&rank=2NLM Identifier: NCT00793598. Accessed February 13, 2009
  171. McGuigan C, Pathirana RN, Migliore M, Adak R, Luoni G, Jones AT, et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother. 2007;60:1316–1330
  172. Canas SM, Wargin B, Boehlecke B, Henson G, Patti JM, Morris AM. A single accelerating dose study to evaluate safety and pharmacokinetics (PK) of FV-100 in healthy subjects. Abstracts of the 21st International Conference on Antiviral Research; 13–17 April 2008; Montreal, Quebec Antiviral Res. 2008;A32:40
  173. Betz UA, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother. 2002;46:1766–1772
  174. Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother. 2007;18:35–48
  175. Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 2007;75:30–35
  176. Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med. 2002;8:386–391
  177. Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med. 2002;8:392–398
  178. Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007;51:3346–3353
  179. National Institutes of Health. Safety, tolerability and pharmacokinetic study of single and multiple intravenous doses of RSV604 in healthy subjects. In: ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00416442?term=rsv-604&rank=1NLM Identifier: NCT00416442. Accessed February 13, 2009
  180. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother. 1999;43:1616–1620
  181. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001;45:3403–3408
  182. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006;69:39–45
  183. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008;78:91–102
  184. Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology. 2008;374:198–209
  185. Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother. 2004;48:4542–4549
  186. National Institutes of Health. A multinational phase III study of CS-8958 (MARVEL). In: ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT00803595?term=cs-8958&rank=1NLM Identifier: NCT00803595. Accessed February 13, 2009
  187. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46:977–981
  188. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49:981–986
  189. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007;51:845–851
  190. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006;50:1470–1479
  191. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007;196:1493–1499
  192. Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med. 2002;8:386–391
  193. Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med. 2002;8:392–398
  194. De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008;13:393–416
  195. Zacny VL, Gershburg E, Davis MG, Biron KK, Pagano JS. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H benzamidazole. J Virol. 1999;73:7271–7277
  196. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18:233–246
  197. Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol. 2008;82:246–253
  198. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–5410

PII: S0037-1963(09)00059-6

doi: 10.1053/j.seminhematol.2009.03.004

Seminars in Hematology
Volume 46, Issue 3 , Pages 230-247 , July 2009

Article Tools